Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical firm Charleston Laboratories has started its second clinical development program with the initiation of patient enrollment in a Phase I trial of its migraine drug candidate, CL-H1T.
Subscribe to our email newsletter
CL-H1T, which contains fast-dissolving promethazine and sumatriptan, is being developed to treat migraine headache pain and migraine-induced nausea and vomiting (MINV).
Charleston Laboratories chief scientific officer Bernard Schachtel said: "Many patients with migraine headaches also suffer from nausea and vomiting.
"CL-H1T contains a known medication for migraine headache with specially formulated promethazine, a safe and effective anti-emetic medication.
"This Phase I trial will identify the bioavailability of both active ingredients in this new combination treatment."
Currently, the company has a development and commercialization partner Daiichi Sankyo for its first product, CL-108, which is completing Phase III clinical trials.
Recently, the company entered into a strategic collaboration for the development and US commercialization of its new hydrocodone combination products, including CL-108, being studied to treat moderate to severe acute pain as well as the prevention of opioid-induced nausea and vomiting (OINV).